About ISCM
>> Mission Statement
>> Statutes
>> Board
>> Support Us
Laboratory Research
>> Cardiovascular Disease
>> Cancer
>> Other Research
Research Archive
>> Cellular Health Research
>> Studies Worldwide
Health News
>> Natural Health
>> Business With Disease
>> Other News
>> News Archive
World Health
>> Who is WHO?
>> Stop Codex!
>> Defend DSHEA
>> Health for All
|
In vitro inactivation of human immunodeficiency
virus by ascorbic acid.
Biologicals 1995 Mar;23(1):75-81 (ISSN: 1045-1056)
Rawal BD; Bartolini F; Vyas GN Department of Laboratory Medicine,
University of California, San Francisco 94143-0134, USA.
In vitro inactivation of cell-free human immunodeficiency virus (CFHIV)
was investigated by mixing replication-competent virions with aliquots of
a culture medium (RPMI) containing increasing amounts (62.5-500 micrograms/ml)
of ascorbic acid (AA) at pH7. Similarly, mixtures of CFHIV and 500 micrograms/ml
AA in whole blood (WB) and leukocyte depleted blood (LDB) were made; control
mixtures containing either CFHIV or AA alone in each experiment were included.
After holding the mixtures for 3 h at 4 degrees C, the tubes containing
WB and LDB mixtures were centrifuged to remove the blood cells. The respective
supernatants, including the control aliquots, were layered over 0.5 x 10(6)
MT2 cells in quadruplicate wells in microtitre plates. After 1 h of incubation
at 37 degrees C in an atmosphere of 5.0% carbon dioxide to permit contact
of viable virions, the fluid in each well was replaced with RPMI containing
20% fetal bovine serum (FBS). The incubation was then continued at 37 degrees
C for 5 days. On the basis of (1) absence of syncytia formation, (2) 100%
viability of MT2 cells as compared with the cell controls, (3) absence of
p24 antigen in the culture supernates, and (4) absence of HIV DNA in MT2
cells, we conclude that 500 micrograms/ml AA, in (a) RPMI, (b) WB, or (c)
LDB, inactivated CFHIV in vitro. Furthermore, we determined that addition
of 500 micrograms/ml AA to platelet concentrates did not adversely affect
the platelet function tests during 5 days of storage at room temperature.
These data warrant further work to evaluate the mechanism of CFHIV inactivation
by treatment of blood products with AA.
|
|